-+ 0.00%
-+ 0.00%
-+ 0.00%

UK MHRA expands Rhythm’s IMCIVREE authorization to treat acquired hypothalamic obesity

PUBT·08/11/2026 12:03:49
Listen to the news
UK MHRA expands Rhythm’s IMCIVREE authorization to treat acquired hypothalamic obesity
  • UK MHRA expanded IMCIVREE (setmelanotide) authorization for acquired hypothalamic obesity in patients aged 4 and older.
  • Decision also granted orphan drug designation for acquired hypothalamic obesity.
  • Phase 3 TRANSCEND showed a -19.8% placebo-adjusted BMI reduction at 52 weeks (p<0.0001).
  • Rhythm plans to work with the NHS to finalize coverage guidance for the new indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110800PRIMZONEFULLFEED9807646) on August 11, 2026, and is solely responsible for the information contained therein.